GLP-1
GLP-1
GLP-1
Semaglutide (Ozempic & Wegovy): The Complete Guide to Dosing, Weight Loss, and Safety
Semaglutide has become one of the most talked-about medications in modern medicine — and for good reason. Marketed under the brand names Ozempic and Wegovy, semaglutide has demonstrated remarkable results for both type 2 diabetes management and long-term weight loss. In this guide, we break down how semaglutide works, what the
GLP-1
Amycretin: The Dual GLP-1/Amylin Peptide That Could Surpass Wegovy
GLP-1
Retatrutide Complete Guide: The Triple GLP-1/GIP/Glucagon Agonist That's Rewriting Obesity Medicine (2026)
Retatrutide may be the most powerful obesity drug ever tested. In Phase 3 clinical trials, Eli Lilly's triple hormone receptor agonist produced average weight loss of up to 28.7% of body weight — surpassing every GLP-1 medication that came before it, including tirzepatide's impressive 20–22%
GLP-1
Tirzepatide (Mounjaro/Zepbound) Complete Guide: Dosing, Benefits, Side Effects & Comparison to Semaglutide (2026)
Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for weight loss — is one of the most significant advances in metabolic medicine in decades. As the first and only FDA-approved dual GIP/GLP-1 receptor agonist, it consistently outperforms older GLP-1 medications like semaglutide in head-to-head trials. This guide covers
GLP-1
Orforglipron (Foundayo): The Oral GLP-1 Pill — Complete Guide (2026)
The first oral GLP-1 pill with no food or timing restrictions. Everything you need to know about orforglipron (Foundayo): mechanism, clinical results, side effects, dosing, and cost.
GLP-1
Semaglutide (Ozempic/Wegovy): The Complete Guide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has reshaped the landscape of obesity medicine and type 2 diabetes management. Originally developed by Novo Nordisk, semaglutide mimics a naturally occurring gut hormone that regulates appetite, blood sugar, and digestion. It is currently available under three brand names: * Ozempic — injectable
GLP-1
Retatrutide: The Triple Agonist GLP-1 Drug That Could Outperform Ozempic and Mounjaro
A new era in obesity medicine may be arriving sooner than most people realize. Retatrutide — developed by Eli Lilly under the research code LY3437943 — is not just another GLP-1 drug. It is the world's first triple hormone receptor agonist to reach late-stage clinical trials, simultaneously activating the GLP-1,
GLP-1
Tirzepatide (Mounjaro/Zepbound) Complete Guide: Dosing, Weight Loss Results, Side Effects & Comparison to Semaglutide (2026)
Compounding
Compounding Pharmacies and Peptides: 503A vs. 503B, Legal Status, and How to Find a Reputable Source (2026)
GLP-1
Orforglipron (Foundayo) Complete Guide: The First Oral GLP-1 Weight Loss Pill (2026)
Orforglipron (Foundayo) received FDA approval in April 2026 as the first non-peptide oral GLP-1 receptor agonist for weight management. Here's everything you need to know about how it works, what the trials showed, and how it compares to injectable GLP-1 drugs.
GLP-1
Retatrutide: The Triple Agonist Weight Loss Drug Explained
A new class of weight-loss medication is rewriting the record books. Retatrutide (LY3437943), developed by Eli Lilly, is the world's first triple receptor agonist approved for obesity clinical trials — simultaneously targeting three metabolic pathways to produce weight loss that was previously considered impossible with a single drug. In